Gene · 6891
Papers2,915
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,915
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer. | Cancers (Basel) | 2023 | 38067409 | PubTator, text mining | PubMed |
| Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. | Cancers (Basel) | 2023 | 38067396 | PubTator, text mining | PubMed |
| Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases. | Cancers (Basel) | 2023 | 38067336 | PubTator, text mining | PubMed |
| An Ancestral Major Histocompatibility Complex Organization in Cartilaginous Fish: Reconstructing MHC Origin and Evolution. | Mol Biol Evol | 2023 | 38059517 | PubTator, text mining | PubMed |
Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. | Front Oncol | 2023 | 38053658 | PubTator, text mining | PubMed |
| Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. | Mol Cancer | 2023 | 38041084 | PubTator, text mining | PubMed |
| Shedding Light on the Role of ERAP1 in Axial Spondyloarthritis. | Cureus | 2023 | 38024089 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma. | J Exp Clin Cancer Res | 2023 | 37993874 | PubTator, text mining | PubMed |
| Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ. | Cancer Res Commun | 2023 | 37991387 | PubTator, text mining | PubMed |
| LMP2 and TAP2 impair tumor growth and metastasis by inhibiting Wnt/β-catenin signaling pathway and EMT in cervical cancer. | BMC Cancer | 2023 | 37986152 | PubTator, text mining | PubMed |
| Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. | Cancers (Basel) | 2023 | 37958409 | PubTator, text mining | PubMed |
| Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect. | J Transl Med | 2023 | 37932756 | PubTator, text mining | PubMed |
| MmuPV1 E6 induces cell proliferation and other hallmarks of cancer. | mBio | 2023 | 37905801 | PubTator, text mining | PubMed |
| The role of ATP binding cassette (ABC) transporters in breast cancer: Evaluating prognosis, predicting immunity, and guiding treatment. | Channels (Austin) | 2023 | 37905302 | PubTator, text mining | PubMed |
| Hormone Receptor Signaling and Breast Cancer Resistance to Anti-Tumor Immunity. | Int J Mol Sci | 2023 | 37894728 | PubTator, text mining | PubMed |
| CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification. | Cells | 2023 | 37887301 | PubTator, text mining | PubMed |
| Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer. | Lipids Health Dis | 2023 | 37885013 | PubTator, text mining | PubMed |
| Advancements in CRISPR screens for the development of cancer immunotherapy strategies. | Mol Ther Oncolytics | 2023 | 37876793 | PubTator, text mining | PubMed |
| Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing. | Front Oncol | 2023 | 37869102 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6891/papers?page=7